Susanna N Visser1, Rebecca H Bitsko2, Melissa L Danielson2, Reem M Ghandour3, Stephen J Blumberg4, Laura A Schieve2, Joseph R Holbrook2, Mark L Wolraich5, Steven P Cuffe6. 1. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: svisser@cdc.gov. 2. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA. 3. Maternal and Child Health Bureau, Health Resources and Services Administration, Rockville, MD. 4. National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD. 5. Oklahoma University Child Study Center, Oklahoma City, OK. 6. Department of Psychiatry, University of Florida College of Medicine-Jacksonville, Jacksonville, FL.
Abstract
OBJECTIVES: To describe the parent-reported prevalence of treatments for attention deficit/hyperactivity disorder (ADHD) among a national sample of children with special health care needs (CSHCN), and assess the alignment of ADHD treatment with current American Academy of Pediatrics guidelines. STUDY DESIGN: Parent-reported data from the 2009-2010 National Survey of Children with Special Health Care Needs allowed for weighted national and state-based prevalence estimates of medication, behavioral therapy, and dietary supplement use for ADHD treatment among CSHCN aged 4-17 years with current ADHD. National estimates were compared across demographic groups, ADHD severity, and comorbidities. Medication treatment by drug class was described. RESULTS: Of CSHCN with current ADHD, 74.0% had received medication treatment in the past week, 44.0% had received behavioral therapy in the past year, and 10.2% used dietary supplements for ADHD in the past year. Overall, 87.3% had received past week medication treatment or past year behavioral therapy (both, 30.7%; neither, 12.7%). Among preschool-aged CSHCN with ADHD, 25.4% received medication treatment alone, 31.9% received behavioral therapy alone, 21.2% received both treatments, and 21.4% received neither treatment. Central nervous system stimulants were the most common medication class (84.8%) among CSHCN with ADHD, followed by the selective norepinephrine reuptake inhibitor atomoxetine (8.4%). CONCLUSION: These estimates provide a benchmark of clinical practice for the period directly preceding issuance of the American Academy of Pediatrics' 2011 ADHD guidelines. Most children with ADHD received medication treatment or behavioral therapy; just under one-third received both. Multimodal treatment was most common for CSHCN with severe ADHD and those with comorbidities. Approximately one-half of preschoolers received behavioral therapy, the recommended first-line treatment for this age group. Published by Elsevier Inc.
OBJECTIVES: To describe the parent-reported prevalence of treatments for attention deficit/hyperactivity disorder (ADHD) among a national sample of children with special health care needs (CSHCN), and assess the alignment of ADHD treatment with current American Academy of Pediatrics guidelines. STUDY DESIGN: Parent-reported data from the 2009-2010 National Survey of Children with Special Health Care Needs allowed for weighted national and state-based prevalence estimates of medication, behavioral therapy, and dietary supplement use for ADHD treatment among CSHCN aged 4-17 years with current ADHD. National estimates were compared across demographic groups, ADHD severity, and comorbidities. Medication treatment by drug class was described. RESULTS: Of CSHCN with current ADHD, 74.0% had received medication treatment in the past week, 44.0% had received behavioral therapy in the past year, and 10.2% used dietary supplements for ADHD in the past year. Overall, 87.3% had received past week medication treatment or past year behavioral therapy (both, 30.7%; neither, 12.7%). Among preschool-aged CSHCN with ADHD, 25.4% received medication treatment alone, 31.9% received behavioral therapy alone, 21.2% received both treatments, and 21.4% received neither treatment. Central nervous system stimulants were the most common medication class (84.8%) among CSHCN with ADHD, followed by the selective norepinephrine reuptake inhibitor atomoxetine (8.4%). CONCLUSION: These estimates provide a benchmark of clinical practice for the period directly preceding issuance of the American Academy of Pediatrics' 2011 ADHD guidelines. Most children with ADHD received medication treatment or behavioral therapy; just under one-third received both. Multimodal treatment was most common for CSHCN with severe ADHD and those with comorbidities. Approximately one-half of preschoolers received behavioral therapy, the recommended first-line treatment for this age group. Published by Elsevier Inc.
Authors: Brent D Fulton; Richard M Scheffler; Stephen P Hinshaw; Peter Levine; Susan Stone; Timothy T Brown; Sepideh Modrek Journal: Psychiatr Serv Date: 2009-08 Impact factor: 3.084
Authors: Stephanie L Mayne; Michelle E Ross; Lihai Song; Banita McCarn; Jennifer Steffes; Weiwei Liu; Benyamin Margolis; Romuladus Azuine; Edward Gotlieb; Robert W Grundmeier; Laurel K Leslie; Russell Localio; Richard Wasserman; Alexander G Fiks Journal: Pediatrics Date: 2016-04-01 Impact factor: 7.124
Authors: Melissa L Danielson; Rebecca H Bitsko; Reem M Ghandour; Joseph R Holbrook; Michael D Kogan; Stephen J Blumberg Journal: J Clin Child Adolesc Psychol Date: 2018-01-24
Authors: David J Kolko; Jonathan A Hart; John Campo; Dara Sakolsky; Jeffrey Rounds; Mark L Wolraich; Stephen R Wisniewski Journal: Clin Pediatr (Phila) Date: 2020-07 Impact factor: 1.168
Authors: Melissa L Danielson; Susanna N Visser; Mary Margaret Gleason; Georgina Peacock; Angelika H Claussen; Stephen J Blumberg Journal: J Dev Behav Pediatr Date: 2017-09 Impact factor: 2.225
Authors: Alexander G Fiks; Michelle E Ross; Stephanie L Mayne; Lihai Song; Weiwei Liu; Jennifer Steffes; Banita McCarn; Robert W Grundmeier; A Russell Localio; Richard Wasserman Journal: Pediatrics Date: 2016-11-15 Impact factor: 7.124